MCCLEAN, VA, UNITED STATES, December 16, 2024 /EINPresswire / -- Perthera, the leader in AI-driven Precision Oncology Decision Support, has unveile ...
From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.
Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ...
Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...
On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San ...
MALMO, SWEDEN / ACCESSWIRE / December 17, 2024 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that two scientific abs ...
On the morning of2, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) ...
The trillions of microbial cells in our gastrointestinal tract have their own genomes and metabolic products, many of which ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either ...
T-DXd improves progression-free survival vs physician’s choice, regardless of time to progression or endocrine resistance, in ...
A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback